前蛋白转化酶枯草溶菌素/kexin 9型功能缺失对感染性休克患儿有害
该研究纳入17家参与机构的522例感染性休克患儿,并在14日龄幼鼠和10–14周龄成年小鼠中建立盲肠浆液脓毒症模型,探讨PCSK9功能缺失对宿主的影响。结果显示,PCSK9功能缺失遗传变异与患儿并发症病程和死亡的比值比升高独立相关;发生并发症病程的患儿PCSK9、低密度脂蛋白和高密度脂蛋白浓度均低于未发生者;PCSK9浓度与促炎细胞因子白介素-8呈负相关。在幼鼠中PCSK9功能缺失降低生存率,而在成年小鼠中提高生存率;幼鼠PCSK9功能缺失导致脂蛋白降低并减少肝脏细菌负荷。作者结论认为,与成年宿主不同,PCSK9功能缺失对感染性休克幼年宿主有害,儿童应被排除在涉及PCSK9抑制剂的脓毒症临床试验之外。
要点
- 522例感染性休克患儿中,PCSK9功能缺失遗传变异与并发症病程和死亡的比值比升高独立相关。
- 发生并发症病程的患儿PCSK9、低密度脂蛋白和高密度脂蛋白浓度低于未发生并发症病程者。
- 患儿PCSK9浓度与促炎细胞因子白介素-8呈负相关。
- 幼鼠(14日龄)PCSK9功能缺失降低脓毒症生存率,而成年小鼠(10–14周龄)PCSK9功能缺失提高生存率。
- 作者认为,涉及PCSK9抑制剂的脓毒症临床试验应排除儿童。
适用人群与场景
- 522例感染性休克患儿,来自17家参与机构,为前瞻性纳入队列。
- 实验使用14日龄幼鼠和10–14周龄成年小鼠,包括组成型PCSK9缺失小鼠和C57BL/6野生型对照小鼠。
研究设计与关键结果
- 研究类型为前瞻性纳入的感染性休克患儿队列加实验小鼠研究,共522例患儿,来自17家参与机构。
- 患儿中PCSK9功能缺失遗传变异与并发症病程和死亡的比值比升高独立相关。
- 发生并发症病程的患儿PCSK9、低密度脂蛋白和高密度脂蛋白浓度低于未发生并发症病程者。
- 患儿PCSK9浓度与促炎细胞因子白介素-8呈负相关。
- 在盲肠浆液脓毒症模型中,PCSK9功能缺失降低幼鼠生存率,但提高成年小鼠生存率。
- 幼鼠中PCSK9功能缺失导致脂蛋白降低并减少肝脏细菌负荷。
证据类型、等级与局限
- 证据类型为前瞻性纳入的儿童队列研究加实验小鼠研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与成年宿主相反,PCSK9功能缺失对感染性休克幼年宿主有害。
- 作者认为,PCSK9功能缺失在低脂蛋白背景下可能导致感染性休克幼年宿主肝脏细菌清除减少。
- 作者认为,涉及PCSK9抑制剂的脓毒症临床试验应排除儿童。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Proprotein convertase subtilisin/kexin type 9 is a central regulator of lipid metabolism and has been implicated in regulating the host response to sepsis. Proprotein convertase subtilisin/kexin type 9 loss-of-function is associated with improved sepsis outcomes in the adult host through increased hepatic bacterial clearance. Thus, there is interest in leveraging proprotein convertase subtilisin/kexin type 9 inhibitors as a therapeutic strategy in adults with sepsis. We sought to validate this association in children with septic shock and in a juvenile murine model of sepsis.
DESIGN: Prospectively enrolled cohort of children with septic shock; experimental mice.
SETTING: Seventeen participating institutions; research laboratory.
PATIENTS AND SUBJECTS: Five-hundred twenty-two children with septic shock; juvenile (14 d old) and adult (10-14 wk) mice with constitutive proprotein convertase subtilisin/kexin type 9 null and wildtype control mice (C57BL/6).
INTERVENTIONS: Proprotein convertase subtilisin/kexin type 9 single-nucleotide polymorphisms, serum proprotein convertase subtilisin/kexin type 9, and lipid profiles in patients. Cecal slurry murine model of sepsis; survival studies in juvenile and adult mice, assessment of lipoprotein fractions, bacterial burden, and inflammation in juvenile mice.
MEASUREMENTS AND MAIN RESULTS: PCSK9 loss-of-function genetic variants were independently associated with increased odds of complicated course and mortality in children with septic shock. PCSK9, low-density lipoprotein, and high-density lipoprotein concentrations were lower among patients with complicated course relative to those without. PCSK9 concentrations negatively correlated with proinflammatory cytokine interleukin-8. Proprotein convertase subtilisin/kexin type 9 loss-of-function decreased survival in juvenile mice, but increased survival in adult mice with sepsis. PCSK9 loss-of-function resulted in low lipoproteins and decreased hepatic bacterial burden in juvenile mice.
CONCLUSIONS: In contrast to the adult host, proprotein convertase subtilisin/kexin type 9 loss-of-function is detrimental to the juvenile host with septic shock. PCSK9 loss-of-function, in the context of low lipoproteins, may result in reduced hepatic bacterial clearance in the juvenile host with septic shock. Our data indicate that children should be excluded in sepsis clinical trials involving proprotein convertase subtilisin/kexin type 9 inhibitors.
参考来源
- Atreya MR, Whitacre BE, Cvijanovich NZ, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock. Crit Care Med. 2020. PMID: 32769621. doi:10.1097/CCM.0000000000004487
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。